A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase II/III Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With Moderate to Severe Systemic Lupus Erythematosus

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase II/III Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With Moderate to Severe Systemic Lupus Erythematosus

Completed
Phase of Trial: Phase II/III

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Rituximab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Acronyms EXPLORER
  • Sponsors Genentech
  • Most Recent Events

    • 17 Jun 2017 Results of reanalysis of EXPLORER trial's raw data using the newly described SLE response criteria, presented at the 18th Annual Congress of the European League Against Rheumatism
    • 28 Dec 2009 Results published in Arthritis & Rheumatism.
    • 08 Oct 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top